TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HURA TuHURA Biosciences, Inc.

盘后交易 02-02 16:54:31 EST

0.5189

-0.0162

-3.03%

盘后0.5047

-0.0142-2.74%

16:54 EST

最高0.7500	最低0.5005	成交量2,029万
今开0.5600	昨收0.5351	日振幅46.63%
总市值3,151万	流通市值2,817万	总股本6,072万
成交额1,286万	换手率37.38%	流通股本5,429万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":0.5189,"timestamp":1770066000000,"preClose":0.5351,"halted":0,"volume":20292379,"hourTrading":{"tag":"盘后","latestPrice":0.5047,"preClose":0.5189,"latestTime":"16:54 EST","volume":99942,"amount":50436.563816279995,"timestamp":1770069253401,"change":-0.0142,"changeRate":-0.027366,"amplitude":0.034881},"delay":0,"changeRate":-0.030274715006540817,"floatShares":54286373,"shares":60720508,"eps":-0.662671,"marketStatus":"盘后交易","change":-0.0162,"latestTime":"02-02 16:54:31 EST","open":0.56,"high":0.75,"low":0.5005,"amount":12860657.20729136,"amplitude":0.466268,"askPrice":0.5409,"askSize":900,"bidPrice":0.5046,"bidSize":1106,"shortable":3,"etf":0,"ttmEps":-0.662671,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1770080400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.5351,"preHourTrading":{"tag":"盘前","latestPrice":0.56,"preClose":0.5351,"latestTime":"09:28 EST","volume":459777,"amount":269702.7513819,"timestamp":1770042480096,"change":0.0249,"changeRate":0.046533,"amplitude":0.331153},"postHourTrading":{"tag":"盘后","latestPrice":0.5047,"preClose":0.5189,"latestTime":"16:54 EST","volume":99942,"amount":50436.563816279995,"timestamp":1770069253401,"change":-0.0142,"changeRate":-0.027366,"amplitude":0.034881},"volumeRatio":68.969337},"requestUrl":"/m/hq/s/HURA","defaultTab":"news","newsList":[{"id":"1169978766","title":"TuHURA Biosciences获FDA孤儿药认定 IFX-2.0有望治疗IIb至IV期皮肤黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1169978766","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169978766?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:45","pubTimestamp":1770036316,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. (以下简称TuHURA) 宣布，其研发的候选药物IFX-2.0已获得美国食品药品监督管理局（FDA）授予的孤儿药资格认定，适应症为IIb期至IV期皮肤黑色素瘤。\n孤儿药认定旨在鼓励针对罕见病的新药研发。获得该认定意味着IFX-2.0在针对这一特定阶段的黑色素瘤治疗方面，有望在药物开发及后续商业化进程中享受一系列政策支持，包括临床试验费用税收抵免、FDA用户费减免以及药物获批后七年的市场独占权。\n此次认定标志着IFX-2.0在治疗晚期皮肤黑色素瘤的研发道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2601937463","title":"Tuhura Biosciences, Inc.盘中异动 股价大涨6.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601937463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601937463?lang=zh_cn&edition=full","pubTime":"2026-01-08 04:02","pubTimestamp":1767816142,"startTime":"0","endTime":"0","summary":"北京时间2026年01月08日04时02分，Tuhura Biosciences, Inc.股票出现异动，股价急速上涨6.74%。Tuhura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为3.15%。其相关个股中，Revolution Medicines Inc C/Wts 17/12/2026 、Lexaria Bioscience Corp C/Wts 14/01/2026 、Erasca, Inc.涨幅较大，Cardio Diagnostics Holdings Inc.、Pmgc Holdings Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为1093.70%、682.96%、351.70%，振幅较大的相关个股有Revolution Medicines Inc C/Wts 17/12/2026 、Erasca, Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为202.13%、67.49%、50.85%。Tuhura Biosciences, Inc.公司简介：TuHURA Biosciences Inc 是一家处于 3 期注册阶段的免疫肿瘤公司，致力于开发克服癌症免疫治疗耐药性的新技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108040222a6ffe016&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108040222a6ffe016&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"1150512948","title":"Tuhura Biosciences发布Kintara的应急价值权（CVR），因Kintara的Rem-001达到了主要安全目标，实现合同里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1150512948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150512948?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:50","pubTimestamp":1765803053,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences发布Kintara的应急价值权（CVR），因Kintara的Rem-001达到了主要安全目标，实现合同里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"1183862465","title":"Tuhura Biosciences展示数据显示，Delta阿片受体（Dor）作为克服对免疫检查点抑制剂获得性耐药的新靶点，亮相第57届ASH年会暨博览会","url":"https://stock-news.laohu8.com/highlight/detail?id=1183862465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183862465?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:51","pubTimestamp":1765198302,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences展示数据显示，Delta阿片受体（Dor）作为克服对免疫检查点抑制剂获得性耐药的新靶点，亮相第57届ASH年会暨博览会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"1115688327","title":"Tuhura Biosciences Inc申请最高2.5亿美元的混合货架注册","url":"https://stock-news.laohu8.com/highlight/detail?id=1115688327","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115688327?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:31","pubTimestamp":1763569873,"startTime":"0","endTime":"0","summary":"11月4日 - TuHURA Biosciences Inc宣布，已向SEC提交申请，计划进行最高达2.5亿美元的混合货架注册。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"1152480810","title":"Tuhura Biosciences Inc：与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1152480810","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152480810?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:23","pubTimestamp":1762259005,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc：与H.C. Wainwright签订Atm协议以出售高达5000万美元的普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2516049635","title":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖，给予买入评级, 目标价13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516049635","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516049635?lang=zh_cn&edition=full","pubTime":"2025-03-03 21:20","pubTimestamp":1741008040,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖，给予买入评级, 目标价13.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03212048493051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HURA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintara.com","stockEarnings":[{"period":"1week","weight":-0.1986},{"period":"1month","weight":-0.2929},{"period":"3month","weight":-0.7902},{"period":"6month","weight":-0.777},{"period":"1year","weight":-0.8912},{"period":"ytd","weight":-0.2929}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.0145},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1437},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TuHURA Biosciences, Inc.是一家内华达州公司，成立于2009年6月24日，名称为Berry Only，Inc。该公司是一家临床阶段的生物制药公司。Kintara致力于为医疗需求未得到满足的患者开发新型癌症疗法。Kintara公司正在开发两种晚期疗法，以降低风险，满足明确的未满足的医疗需求。这两个项目分别是VAL-083治疗胶质母细胞瘤（GBM）和REM-001治疗皮肤转移性乳腺癌（CMBC）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.054973},{"month":2,"riseRate":0.111111,"avgChangeRate":-0.150578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.000318},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.030862},{"month":5,"riseRate":0.555556,"avgChangeRate":1.198143},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.040545},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.01467},{"month":8,"riseRate":0.5,"avgChangeRate":-0.086193},{"month":9,"riseRate":0.3,"avgChangeRate":-0.103258},{"month":10,"riseRate":0.4,"avgChangeRate":-0.116072},{"month":11,"riseRate":0.4,"avgChangeRate":-0.068131},{"month":12,"riseRate":0.2,"avgChangeRate":-0.220735}],"exchange":"NASDAQ","name":"TuHURA Biosciences, Inc.","nameEN":"TuHURA Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TuHURA Biosciences, Inc.,HURA,TuHURA Biosciences, Inc.股票,TuHURA Biosciences, Inc.股票老虎,TuHURA Biosciences, Inc.股票老虎国际,TuHURA Biosciences, Inc.行情,TuHURA Biosciences, Inc.股票行情,TuHURA Biosciences, Inc.股价,TuHURA Biosciences, Inc.股市,TuHURA Biosciences, Inc.股票价格,TuHURA Biosciences, Inc.股票交易,TuHURA Biosciences, Inc.股票购买,TuHURA Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}